Curebase Raises $40M in Series B Funding
- Curebase, a San Francisco, CA-based technology-driven clinical trial startup, raised $40m in Series B funding
- The round was led by Industry Ventures, with participation from Acrew Capital, World Innovation Lab and Positive Sum, Gaingels, GGV Capital, Bold Capital and Xfund
- The round also included a strategic investment by global biopharmaceutical company Gilead Sciences
- The company, which has raised a total of $59m, intends to use the funds to continue development of its solutions
- The company provides decentralized clinical trials (DCTs) and patient-centric clinical trial software
- The company has now run over 50 studies to date, with 300-400% growth year over year
